Travellers' health and infectious diseases on aircraft
As increasing numbers of people travel by air, the potential risk of introduction and spread of infectious diseases by travellers is on the rise. Figures from Eurostat reveal that around 900 million passengers annually are carried on flights within the European Union (EU) alone.
Protocols for cohort database studies to measure influenza vaccine effectiveness in the EU and EEA Member States
Toolkit for investigation of cases of Avian influenza in humans
In order to increase preparedness to respond to possible cases and clusters of Highly Pathogenic Avian Influenza A/H5N1 in humans in Europe, the ECDC has prepared a toolkit for the European Union member states.
Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA): Influenza
This report which is part of the RAGIDA project (Risk Assessment Guidance for Infectious Diseases transmitted on Aircraft) provides viable options for decision-makers when faced with the choice of whether to contact trace air travellers and crew that were potentially exposed to infectious diseases during a flight.
- Avian influenza virus
- Infectious diseases on aircrafts
- Influenza A (H1N1)2009
- Influenza A(H5N1) virus
- Influenza A(H5N2) virus
- Influenza A(H5N8) virus
- Influenza A(H7N9) virus
- Influenza in humans, avian origin
- Influenza in humans, pandemic
- Influenza in humans, seasonal
- Influenza in humans, swine origin
- Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA)
- Travellers' health
Risk assessment guidelines for infectious diseases transmitted on aircraft
In the closed cabin environment of modern airplanes, passengers are frequently exposed to various infectious diseases. This report looks at 12 infectious diseases and, by systematically evaluating literature on on-board transmission, attempts to assess the risk of infection via air circulation in airplanes.
These guidelines are complemented by operational guidelines in relation to tuberculosis, new emerging airborne diseases (e.g. SARS) and meningococcal infections.
Interim technical guidance on public health use of influenza antivirals during influenza pandemics
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
Protocol for cluster investigations to measure influenza vaccine effectiveness in the EU/EEA
Joint European pandemic preparedness self-assessment indicators
This set of pandemic preparedness indicators is designed to assist Member States with the assessment of their pandemic preparedness in order to identify gaps, prioritise future investment and monitor progress in those areas that, by international consensus, are deemed the most important.
Interim technical guidance on use of specific pandemic influenza vaccines during the H1N1 2009 pandemic
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.